Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2007 3
2024 2
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Data mining in FAERS: association of newer-generation H1-antihistamines with nervous system disorders.
Hu W, Li H, Zeng L, Gan J, Feng C, Chen L, Zhang L. Hu W, et al. BMC Pharmacol Toxicol. 2024 Dec 18;25(1):95. doi: 10.1186/s40360-024-00822-x. BMC Pharmacol Toxicol. 2024. PMID: 39696617 Free PMC article.
CONCLUSION: Neurological AEs associated with individual newer generation H1-antihistamines of interest varies a lot, whereas somnolence was the most common AE reports. Fexofenadine was highly associated with headaches. Sedative effects associated with levocetirizine and ce …
CONCLUSION: Neurological AEs associated with individual newer generation H1-antihistamines of interest varies a lot, whereas somnolence was …
Comparison of Allergic Rhinitis Treatments on Patient Satisfaction: A MASK-air and EAACI Methodological Committee Report.
Sousa-Pinto B, Vieira RJ, Bognanni A, Martini M, Ordak M, Paoletti G, Gil-Mata S, Amaral R, Bedbrook A, Bonadonna P, Brussino L, Canonica GW, Coutinho-Almeida J, Cruz ÁA, Czarlewski W, Dykewicz M, Giovannini M, Gemicioglu B, Ivancevich JC, Klimek L, Kvedariene V, Larenas-Linnemann DE, Marques-Cruz M, Moreira A, Niedoszytko M, Pereira AM, Papadopoulos NG, Pham-Thi N, Regateiro FS, Toppila-Salmi SK, Samolinski B, Sastre J, Taborda-Barata L, Thomander T, Koyuncu IV, Valiulis A, Vecillas LL, Ventura MT, Walusiak-Skorupa J, Xiang YK, Pfaar O, Fonseca JA, Zuberbier T, Schünemann HJ, di Bona D, Bousquet J. Sousa-Pinto B, et al. Allergy. 2025 Dec;80(12):3319-3330. doi: 10.1111/all.70055. Epub 2025 Sep 26. Allergy. 2025. PMID: 41001805 Free PMC article.
When comparing individual intranasal medications, fluticasone furoate and fluticasone propionate tended to be more frequently used in co-medication. Among individual OAH, desloratadine and rupatadine were associated with higher satisfaction, while fexofenadine was more fre …
When comparing individual intranasal medications, fluticasone furoate and fluticasone propionate tended to be more frequently used in co-med …
Desloratadine improves quality of life and symptom severity in patients with allergic rhinitis.
Pradalier A, Neukirch C, Dreyfus I, Devillier P. Pradalier A, et al. Allergy. 2007 Nov;62(11):1331-4. doi: 10.1111/j.1398-9995.2007.01374.x. Epub 2007 May 23. Allergy. 2007. PMID: 17521311 Clinical Trial.
AR signs/symptoms and the global response to therapy were measured at baseline and at day 14; signs/symptoms were also rated AM/PM in patient diaries. Adverse events (AE) were recorded. RESULTS: Overall 234 patients received desloratadine and 249 received placebo. . …
AR signs/symptoms and the global response to therapy were measured at baseline and at day 14; signs/symptoms were also rated AM/PM in patien …
Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR. Bayés M, et al. Methods Find Exp Clin Pharmacol. 2004 Jan-Feb;26(1):53-84. Methods Find Exp Clin Pharmacol. 2004. PMID: 14988742 Review.
This issue focuses on the following selection of drugs: Abetimus sodium, Ad5-FGF4, adeno-Interferon gamma, AE-941, AERx, alemtuzumab, alicaforsen sodium, almotriptan, alpharadin, anakinra, anatumomab mafenatox, ANG-453, anti-CTLA-4 Mab, AP-12009, aprepitant, aripiprazole, …
This issue focuses on the following selection of drugs: Abetimus sodium, Ad5-FGF4, adeno-Interferon gamma, AE-941, AERx, alemtuzumab, …
Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR. Bayés M, et al. Methods Find Exp Clin Pharmacol. 2004 Oct;26(8):639-63. Methods Find Exp Clin Pharmacol. 2004. PMID: 15605126
This issue focuses on the following selection of drugs: Abiraterone acetate, Ad5CMV-p53, adefovir dipivoxil, AE-941, ambrisentan, aripiprazole, atomoxetine hydrochloride, atrasentan; BCH-10618, bimatoprost, BMS-184476, BMS-275183, BMS-387032, botulinum toxin type B, BR-1, …
This issue focuses on the following selection of drugs: Abiraterone acetate, Ad5CMV-p53, adefovir dipivoxil, AE-941, ambrisentan, ari …
Construction of a modified Arrhenius equation for predicting drug nitrosation in solid dosage form.
Takegawa Y, Sugimoto M, Uchiyama H, Kadota K, Tozuka Y. Takegawa Y, et al. Int J Pharm. 2025 Nov 30;685:126212. doi: 10.1016/j.ijpharm.2025.126212. Epub 2025 Sep 26. Int J Pharm. 2025. PMID: 41016588
To prevent contamination by nitrosamine drug substance-related impurities (NDSRIs) in solid dosage forms, the modeling of drug nitrosation reactions was investigated. The nitrosation reaction rate of desloratadine (DES) in the physical mixtures (PMs) was measured under var …
To prevent contamination by nitrosamine drug substance-related impurities (NDSRIs) in solid dosage forms, the modeling of drug nitrosation r …
Impact of a Clinical Decision Support System on the Change over Time in the Anticholinergic Load in Geriatric Patients: The SADP-Antichol Study.
Delvallée G, Mondet L, Cornille C, Deschasse G, Lenglet A. Delvallée G, et al. Pharmacy (Basel). 2024 Oct 30;12(6):162. doi: 10.3390/pharmacy12060162. Pharmacy (Basel). 2024. PMID: 39585088 Free PMC article.
For the targeted drugs (n = 94) over the 87 alerts, 46.8% were for antihistamines and 21.3% were for desloratadine. Of the 36 pharmacist interventions sent by the pharmacist, 19 (52.8%) were accepted. ...Among these 87 patients with alerts, the correlation between the anti …
For the targeted drugs (n = 94) over the 87 alerts, 46.8% were for antihistamines and 21.3% were for desloratadine. Of the 36 pharmac …
Influence of food on the oral bioavailability of rupatadine tablets in healthy volunteers: a single-dose, randomized, open-label, two-way crossover study.
Solans A, Carbó ML, Peña J, Nadal T, Izquierdo I, Merlos M. Solans A, et al. Clin Ther. 2007 May;29(5):900-908. doi: 10.1016/j.clinthera.2007.05.004. Clin Ther. 2007. PMID: 17697908 Clinical Trial.
Plasma concentration-time profiles of desloratadine and 3-hydroxydesloratadine were similar with and without food, and no differences were seen for AUC(0-t), AUC(0-infinity), or C(max). Seven (28%) subjects reported > or =1 AE. All AEs were mild, resolved spontan …
Plasma concentration-time profiles of desloratadine and 3-hydroxydesloratadine were similar with and without food, and no differences …
Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): a randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults.
Antonijoan R, García-Gea C, Puntes M, Pérez J, Esbrí R, Serra C, Fortea J, Barbanoj MJ. Antonijoan R, et al. Clin Ther. 2007 May;29(5):814-822. doi: 10.1016/j.clinthera.2007.05.001. Clin Ther. 2007. PMID: 17697901 Clinical Trial.
Unadjusted mean (SD) wheal areas 24 hours after dose administration on day 5 were 72.9 (29.5), 115.0 (32.1), and 146.7 (32.2) mm(2), for ebastine, desloratadine, and placebo, respectively. Mean differences in reduction from baseline in wheal area were 29.0% for ebastine ve …
Unadjusted mean (SD) wheal areas 24 hours after dose administration on day 5 were 72.9 (29.5), 115.0 (32.1), and 146.7 (32.2) mm(2), for eba …